QualityStocks News - InspireMD Announces Positive Results from MASTER MGuard Stent Trial

Share Article

Company will present “milestone” trial results at upcoming cardiovascular therapeutics meeting in Miami

...key milestone...

QualityStocks would like to highlight InspireMD Inc., a medical device company, focused on the development and commercialization of proprietary MGuard stent platform technology with applications in interventional cardiology and other vascular procedures. Its lead products include MGuard stent, an embolic protection device based on a protective sleeve, which is constructed out of an ultra-thin polymer mesh and wrapped around the stent; and MGuard Prime, which include its mesh sleeve wrapped around a cobalt-chromium stent.

In the company’s news yesterday,

InspireMD announced positive results from a multi-center randomized trial of its MGuard™ embolic protection stent technology used for emergency treatment of patients suffering from heart attacks.

The company will present detailed results from the MASTER trial at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) meeting in Miami in October.

Ofir Paz, InspireMD’s CEO, said the results signify a “key milestone” in the company’s history; the company pointed out that stents for heart attack patients are expected to make up $1.8 billion of stent sales, or nearly 30 percent of the $5.9 billion global stent market.

The MASTER (MGuard forAcute ST Elevation Reperfusion) compared MGuard to commercially approved bare metal or drug-eluting stents. The trial enrolled 433 patients in nine countries.

The MGuard embolic protection stent is a coronary stent integrated with a proprietary micronet technology, which is designed to hold plaque and thrombus in place against the blocked artery’s wall, thereby preventing debris from entering the bloodstream.

The company said that plans for a U.S. FDA registration trial are underway, and that it expects to commence patient enrollment by year end.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Editor
Visit website